Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease

Anna Daunt; Pablo N Perez-Guzman; Felicity Liew; Katharina Hauck; Ceire E Costelloe; Mark R Thursz; Graham Cooke; Shevanthi Nayagam

doi:10.1016/j.jinf.2020.06.049

Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease

J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.049. Epub 2020 Jun 21.

Authors

Anna Daunt¹, Pablo N Perez-Guzman², Felicity Liew³, Katharina Hauck², Ceire E Costelloe⁴, Mark R Thursz⁵, Graham Cooke⁶, Shevanthi Nayagam⁷

Affiliations

¹ MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, United Kingdom; Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, United Kingdom.
² MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, United Kingdom.
³ Respiratory Medicine, Imperial College Healthcare NHS Trust, United Kingdom.
⁴ Global Digital Health Unit, School of Public Health, Imperial College London, United Kingdom.
⁵ Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, United Kingdom.
⁶ MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, United Kingdom; Department of Infectious Diseases, Imperial College London, United Kingdom.
⁷ MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, United Kingdom; Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, United Kingdom. Electronic address: s.nayagam01@imperial.ac.uk.

No abstract available

Keywords: Clinical deterioration; Covid-19; Mortality; Remdesivir; Risk score.

Publication types

Letter
Comment

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections* / drug therapy
Health Services Accessibility
Humans
London
Pandemics*
Pneumonia, Viral*
Retrospective Studies
SARS-CoV-2
State Medicine
United Kingdom

Substances

remdesivir
Adenosine Monophosphate
Alanine

Publication types

MeSH terms

Substances

Grants and funding